Please login to the form below

Access and elimination: the future of DAAs in hepatitis C

Published in Pharmaphorum January 2017

The dramatic improvements in safety, efficacy, tolerability and convenience from the first wave of direct-acting antivirals (DAAs) have made a substantial contribution to changing both the treatment paradigm and the long-term prognosis for hepatitis C. 

The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for some 700,000 deaths globally each year.

http://www.researchpartnership.com/news/2017/01/access-and-elimination-the-future-of-daas-in-hepatit...



25th January 2017

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Article
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma
Research Partnership
Infographic
Migraine market snapshot
Research Partnership
Webinar
Monitoring the impact of COVID-19 on the market access landscape
Research Partnership
Live webinar from Singapore
Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19
Research Partnership
Guide
UX research
Research Partnership
Article: Why pharma must trust the science of behaviour

Research Partnership